Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): Role in the inflammatory response within tumors

Journal of Immunotherapy

Volumn 30, Issue 1, 2007, Pages 16-28

  Lotfi, Ramin ^a   Lee, James J ^b   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Damage associated molecular pattern molecules (DAMPs); Eosinophils; Gastrointestinal tumors; High mobility group box 1 protein (HMGB1); Immunotherapy of cancer

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; NUCLEAR PROTEIN;

ANTIGEN PRESENTING CELL; CELL ACTIVITY; CELL DEATH; CELL INFILTRATION; CELL MIGRATION; CHEMOTAXIS; CLINICAL TRIAL; ENTERITIS; EOSINOPHIL; GASTROINTESTINAL TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; PEYER PATCH; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EOSINOPHILS; GASTROINTESTINAL NEOPLASMS; HMGB1 PROTEIN; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 33845966763     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211324.53396.f6     Document Type: Review

References (194)

1. Zeh HJ III, Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother. 2005;28:1-9.
2. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641-648.
3. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
4. Casares N, Arribillaga L, Sarobe P, et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003;171:5931-5939.
5. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
6. Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia. 2005;7:390-396.
7. Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol. 2004;173:5909-5913.
8. Samoszuk M. Eosinophils and human cancer. Histol Histopathol. 1997;12:807-812.
9. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992;257:548-551.
10. Noffz G, Qin Z, Kopf M, et al. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J Immunol. 1998;160:345-350.
11. Till JE, McCulloch EA, Siminovitch L. A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells. Proc Natl Acad Sci USA. 1964;51:29-36.
12. Parwaresch MR, Walle AJ, Arndt D. The peripheral kinetics of human radiolabelled eosinophils. Virchows Arch B Cell Pathol. 1976;21:57-66.
13. Peled A, Gonzalo JA, Lloyd C, et al. The chemotactic cytokine eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung inflammation. Blood. 1998;91:1909-1916.
14. Kobayashi H. Effect of c-kit ligand (stem cell factor) in combination with interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3, on eosinophil lineage. Int J Hematol. 1993;58:21-26.
15. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989;73:1504-1512.
16. Sanderson CJ. Interleukin-5 and the Regulation of Eosinophil Production. London: Academic Press; 1993.
17. Palframan RT, Collins PD, Severs NJ, et al. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med. 1998;188:1621-1632.
18. Spry CJ, Kay AB, Gleich GJ. Eosinophils 1992. Immunol Today. 1992;13:384-387.
19. Steinbach KH, Schick P, Trepel F, et al. Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut. 1979;39:27-38.
20. Dvorak AM, Ackerman SJ. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to granules and intragranular crystals in mature human basophils. Lab Invest. 1989;60:557-567.
21. Dvorak AM, Weller PF, Monahan-Earley RA, et al. Ultrastructural localization of Charcot-Leyden crystal protein (lysophospholipase) and peroxidase in macrophages, eosinophils, and extracellular matrix of the skin in the hypereosinophilic syndrome. Lab Invest. 1990;62:590-607.
22. Egesten A, Alumets J, von Mecklenburg C, et al. Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique. J Histochem Cytochem. 1986;34:1399-1403.
23. Peters MS, Rodriguez M, Gleich GJ. Localization of human eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin by immunoelectron microscopy. Lab Invest. 1986;54:656-662.
24. Torpier G, Colombel JF, Mathieu-Chandelier C, et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol. 1988;74:404-408.
25. Okuda M, Takenaka T, Kawabori S, et al. Ultrastructural study of the specific granule of the human eosinophil. J Submicrosc Cytol. 1981;13:465-471.
26. Stirling JW. Ultrastructural localization of lysozyme in human colon eosinophils using the protein A-gold technique: effects of processing on probe distribution. J Histochem Cytochem. 1989;37:709-714.
27. Bass DA, Lewis JC, Szejda P, et al. Activation of lysosomal acid phosphatase of eosinophil leukocytes. Lab Invest. 1981;44:403-409.
28. Ghidoni JJ, Goldberg AF. Light and electron microscopic localization of acid phosphatase activity in human eosinophils. Am J Clin Pathol. 1966;45:402-405.
29. Parmley RT, Spicer SS. Cytochemical and ultrastructural identi-fication of a small type granule in human late eosinophils. Lab Invest. 1974;30:557-567.
30. Yokota S, Tsuji H, Kato K. Localization of lysosomal and peroxisomal enzymes in the specific granules of rat intestinal eosinophil leukocytes revealed by immunoelectron microscopic techniques. J Histochem Cytochem. 1984;32:267-274.
31. Iozzo RV, MacDonald GH, Wight TN. Immunoelectron microscopic localization of catalase in human eosinophilic leukocytes. J Histochem Cytochem. 1982;30:697-701.
32. Yokota S, Deimann W, Hashimoto T, et al. Immunocytochemical localization of two peroxisomal enzymes of lipid beta-oxidation in specific granules of rat eosinophils. Histochemistry. 1983;78:425-433.
33. Lungarella G, Menegazzi R, Gardi C, et al. Identification of elastase in human eosinophils: immunolocalization, isolation, and partial characterization. Arch Biochem Biophys. 1992;292:128-135.
34. Levi-Schaffer F, Lacy P, Severs NJ, et al. Association of granulocyte-macrophage colony-stimulating factor with the crystalloid granules of human eosinophils. Blood. 1995;85:2579-2586.
35. Levi-Schaffer F, Barkans J, Newman TM, et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunology. 1996;87:155-161.
36. Moqbel R, Ying S, Barkans J, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol. 1995;155:4939-4947.
37. Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 1994;179:703-708.
38. Lacy P, Levi-Schaffer F, Mahmudi-Azer S, et al. Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon gamma. Blood. 1998;91:2508-2516.
39. Melani C, Mattia GF, Silvani A, et al. Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. Blood. 1993;81:2744-2749.
40. Hamid Q, Barkans J, Meng Q, et al. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood. 1992;80:1496-1501.
41. Costa JJ, Matossian K, Resnick MB, et al. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. J Clin Invest. 1993;91:2673-2684.
42. Beil WJ, Weller PF, Tzizik DM, et al. Ultrastructural immunogold localization of tumor necrosis factor-alpha to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem. 1993;41:1611-1615.
43. Ying S, Meng Q, Taborda-Barata L, et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol. 1996;26:70-76.
44. Blom M, Tool AT, Wever PC, et al. Human eosinophils express, relative to other circulating leukocytes, large amounts of secretory 14-kD phospholipase A2. Blood. 1998;91:3037-3043.
45. Ginsel LA, Onderwater JJ, Fransen JA, et al. Localization of the low-Mr subunit of cytochrome b558 in human blood phagocytes by immunoelectron microscopy. Blood. 1990;76:2105-2116.
46. Bozza PT, Yu W, Penrose JF, et al. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med. 1997;186:909-920.
47. Dvorak AM, Morgan ES, Tzizik DM, et al. Prostaglandin endoperoxide synthase (cyclooxygenase): ultrastructural localization to nonmembrane-bound cytoplasmic lipid bodies in human eosinophils and 3T3 fibroblasts. Int Arch Allergy Immunol. 1994;105:245-250.
48. Dvorak AM, Morgan E, Schleimer RP, et al. Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxygenase) to non-membrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, type II pneumocytes, and neutrophils. J Histochem Cytochem. 1992;40:759-769.
49. Weller PF. Eosinophils: structure and functions. Curr Opin Immunol. 1994;6:85-90.
50. Bozza PT, Yu W, Cassara J, et al. Pathways for eosinophil lipid body induction: differing signal transduction in cells from normal and hypereosinophilic subjects. J Leukoc Biol. 1998;64:563-569.
51. Dvorak AM, Ackerman SJ, Furitsu T, et al. Mature eosinophils stimulated to develop in human-cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. II. Vesicular transport of specific granule matrix peroxidase, a mechanism for effecting piecemeal degranulation. Am J Pathol. 1992;140:795-807.
52. Zabucchi G, Soranzo MR, Menegazzi R, et al. Eosinophilic granuloma of the bone in Hand-Schuller-Christian disease: extensive in vivo eosinophil degranulation and subsequent binding of released eosinophil peroxidase (EPO) to other inflammatory cells. J Pathol. 1991;163:225-231.
53. Monahan RA, Dvorak HF, Dvorak AM. Ultrastructural localization of nonspecific esterase activity in guinea pig and human monocytes, macrophages, and lymphocytes. Blood. 1981;58:1089-1099.
54. Weller PF. The immunobiology of eosinophils. N Engl J Med. 1991;324:1110-1118.
55. Rothenberg ME, Mishra A, Brandt EB, et al. Gastrointestinal eosinophils. Immunol Rev. 2001;179:139-155.
56. Jones RL, Hannan NJ, Kaitu'u TJ, et al. Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. J Clin Endocrinol Metab. 2004;89:6155-6167.
57. Matthews AN, Friend DS, Zimmermann N, et al. Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci USA. 1998;95:6273-6278.
58. Rothenberg ME. Gastrointestinal eosinophils. Allergy. 2001; 56(Suppl 67):21-22.
59. Yang J, Torio A, Donoff RB, et al. Depletion of eosinophil infiltration by anti-IL-5 monoclonal antibody (TRFK-5) accelerates open skin wound epithelial closure. Am J Pathol. 1997;151:813-819.
60. Kato M, Kephart GM, Talley NJ, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec. 1998;252:418-425.
61. Mishra A, Hogan SP, Lee JJ, et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest. 1999;103:1719-1727.
62. Ferguson A. Models of intestinal hypersensitivity. Clin Gastroenterol. 1976;5:271-288.
63. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol. 1999;21:291-295.
64. Kurup VP, Seymour BW, Choi H, et al. Particulate Aspergillus fumigatus antigens elicit a TH2 response in BALB/c mice. J Allergy Clin Immunol. 1994;93:1013-1020.
65. Kurup VP, Mauze S, Choi H, et al. A murine model of allergic bronchopulmonary aspergillosis with elevated eosinophils and IgE. J Immunol. 1992;148:3783-3788.
66. Mishra A, Hogan SP, Brandt EB, et al. Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin. Blood. 2000;96:1538-1544.
67. Lotfi R, DeMarco RA, Lotze MT. Human eosinophilic granulocytes respond to both recombinant and natural HMGB1. Submitted.
68. Komada T, Araki R, Nakatani K, et al. Novel specific chemtactic receptor for S100L protein on guinea pig eosinophils. Biochem Biophys Res Commun. 1996;220:871-874.
69. Golden J, Frim DM, Chapman PH, et al. Marked tissue eosinophilia within organizing chronic subdural hematoma membranes. Clin Neuropathol. 1994;13:12-16.
70. Shen ZJ, Esnault S, Malter JS. The peptidyl-prolyl isomerase Pin1 regulates the stability of granulocyte-macrophage colony-stimulating factor mRNA in activated eosinophils. Nat Immunol. 2005;6:1280-1287.
71. Watanabe Y, Hashizume M, Kataoka S, et al. Differentiation stages of eosinophils characterized by hyaluronic acid binding via CD44 and responsiveness to stimuli. DNA Cell Biol. 2001;20:189-202.
72. Ohkawara Y, Tamura G, Iwasaki T, et al. Activation and transforming growth factor-beta production in eosinophils by hyaluronan. Am J Respir Cell Mol Biol. 2000;23:444-451.
73. Riise GC, Schersten H, Nilsson F, et al. Activation of eosinophils and fibroblasts assessed by eosinophil cationic protein and hyaluronan in BAL. Association with acute rejection in lung transplant recipients. Chest. 1996;110:89-96.
74. Vignola AM, Chanez P, Polla BS, et al. Increased expression of heat shock protein 70 on airway cells in asthma and chronic bronchitis. Am J Respir Cell Mol Biol. 1995;13:683-691.
75. Polla BS, Kantengwa S, Gleich GJ, et al. Spontaneous heat shock protein synthesis by alveolar macrophages in interstitial lung disease associated with phagocytosis of eosinophils. Eur Respir J. 1993;6:483-488.
76. Idzko M, Panther E, Bremer HC, et al. Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br J Pharmacol. 2003;138:1244-1250.
77. Idzko M, Dichmann S, Panther E, et al. Functional characterization of P2Y and P2X receptors in human eosinophils. J Cell Physiol. 2001;188:329-336.
78. Mohanty JG, Raible DG, McDermott LJ, et al. Effects of purine and pyrimidine nucleotides on intracellular Ca2+ in human eosinophils: activation of purinergic P2Y receptors. J Allergy Clin Immunol. 2001;107:849-855.
79. Dichmann S, Idzko M, Zimpfer U, et al. Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca(++) mobilization and actin reorganization in human eosinophils. Blood. 2000;95:973-978.
80. Culley FJ, Fadlon EJ, Kirchem A, et al. Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur J Immunol. 2003;33:1302-1310.
81. Lipscombe RJ, Nakhoul AM, Sanderson CJ, et al. Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix. J Leukoc Biol. 1998;63:342-350.
82. Feistritzer C, Kaneider NC, Sturn DH, et al. Syndecan-4-dependent migration of human eosinophils. Clin Exp Allergy. 2004;34:696-703.
83. Rauvala H, Huttunen HJ, Fages C, et al. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol. 2000;19:377-387.
84. Cormier SA, Taranova AG, Bedient C, et al. Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukocyte Biol. 2006. In press.
85. Lee JJ, Lee NA. Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? Clin Exp Allergy. 2005;35:986-994.
86. Barker RL, Gleich GJ, Pease LR. Acidic precursors revealed in human eosinophil granule major basic protein cDNA. J Exp Med. 1988;168:1493-1498.
87. Plager DA, Loegering DA, Weiler DA, et al. A novel and highly divergent homolog of human eosinophil granule major basic protein. J Biol Chem. 1999;274:14464-14473.
88. Larson KA, Horton MA, Madden BJ, et al. The identification and cloning of a murine major basic protein gene expressed in eosinophils. J Immunol. 1995;155:3002-3012.
89. Macias MP, Welch KC, Denzler KL, et al. The identification of a new murine eosinophil major basic protein (mMBP) gene: cloning and characterization of mMBP-2. J Leukocyte Biol. 2000;67:567-576.
90. Horton MA, Larson KA, Lee JJ, et al. Cloning of the murine eosinophil peroxidase gene (mEPO): characterization of a conserved subgroup of mammalian hematopoietic peroxidases. J Leukoc Biol. 1996;60:285-294.
91. Ten RM, Pease LR, McKean DJ, et al. Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med. 1989;169:1757-1769.
92. Rosenberg HF, Ackerman SJ, Tenen DG. Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med. 1989;170:163-176.
93. Rosenberg HF, Tenen DG, Ackerman SJ. Molecular cloning of the human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. Proc Natl Acad Sci USA. 1989;86:4460-4464.
94. Cormier SA, Larson KA, Yuan S, et al. Mouse Eosinophil-associated ribonucleases: a unique subfamily expressed during hematopoiesis. Mammalian Genome. 2001;12:352-361.
95. Venge P. Eosinophil activity in bronchial asthma. Allergy Proc. 1994;15:139-141.
96. Nagata M, Sedgwick JB, Bates ME, et al. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol. 1995;155:2194-2202.
97. Bandeira-Melo C, Woods LJ, Phoofolo M, et al. Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med. 2002;196:841-850.
98. Henderson WR, Harley JB, Fauci AS. Arachidonic acid metabolism in normal and hypereosinophilic syndrome human eosinophils: generation of leukotrienes B4, C4, D4 and 15-lipoxygenase products. Immunology. 1984;51:679-686.
99. Turk J, Maas RL, Brash AR, et al. Arachidonic acid 15-lipoxygenase products from human eosinophils. J Biol Chem. 1982;257:7068-7076.
100. Bruijnzeel PLB, Verhagen J. Lipid metabolism by eosinophils. In: Morley J, Colditz I, eds. Eosinophils in Asthma. San Diego: Academic Press; 1989:69-85.
101. Lee T, Lenihan DJ, Malone B, et al. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984;259:5526-5530.
102. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci. 1995;16:304-309.
103. Ford-Hutchinson AW, Bray MA, Doig MV, et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980;286:264-265.
104. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med. 1998;157:S210-213; discussion S247-218.
105. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144-2148.
106. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112:1029-1036.
107. Denzler KL, Farmer SC, Crosby JR, et al. Eosinophil major basic protein-1 does not contribute to allergen-induced airway pathologies in mouse models of asthma. J Immunol. 2000;165:5509-5517.
108. Denzler KL, Borchers MT, Crosby JR, et al. Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol. 2001;167:1672-1682.
109. Stelts D, Egan RW, Falcone A, et al. Eosinophils retain their granule major basic protein in a murine model of allergic pulmonary inflammation. Am J Respir Cell Mol Biol. 1998;18:463-470.
110. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776-1779.
111. Lee JJ, Dimina D, Macias MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773-1776.
112. Stenfeldt AL, Wenneras C. Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology. 2004;112:605-614.
113. Lucey DR, Nicholson-Weller A, Weller PF. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci USA. 1989;86:1348-1351.
114. Weller PF, Rand TH, Barrett T, et al. Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression. J Immunol. 1993;150:2554-2562.
115. Shi HZ, Humbles A, Gerard C, et al. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest. 2000;105:945-953.
116. Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med. 2002;195:1433-1444.
117. Padigel UM, Lee JJ, Nolan TJ, et al. Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to strongyloides stercoralis. Infect Immunity. In press.
118. Duez C, Dakhama A, Tomkinson A, et al. Migration and accumulation of eosinophils toward regional lymph nodes after airway allergen challenge. J Allergy Clin Immunol. 2004;114:820-825.
119. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev. 1999;51:213-340.
120. Wong DT, Weller PF, Galli SJ, et al. Human eosinophils express transforming growth factor alpha. J Exp Med. 1990;172:673-681.
121. Fujisawa T, Fukuda S, Atsuta J, et al. Interferon-gamma induces interleukin-3 release from peripheral blood eosinophils. Int Arch Allergy Immunol. 1994;104(Suppl 1):41-43.
122. Moller GM, de Jong TA, van der Kwast TH, et al. Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol. 1996;14:439-443.
123. Yousefi S, Hemmann S, Weber M, et al. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J Immunol. 1995;154:5481-5490.
124. Simon HU, Yousefi S, Weber M, et al. Human peripheral blood eosinophils express and release interleukin-8. Int Arch Allergy Immunol. 1995;107:124-126.
125. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest. 1992;90:1414-1424.
126. Lim KG, Wan HC, Bozza PT, et al. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol. 1996;156:2566-2570.
127. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol. 1997;17:70-77.
128. Woerly G, Lacy P, Younes AB, et al. Human eosinophils express and release IL-13 following CD28-dependent activation. J Leukoc Biol. 2002;72:769-779.
129. Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001;108:430-438.
130. Hartman M, Piliponsky AM, Temkin V, et al. Human peripheral blood eosinophils express stem cell factor. Blood. 2001;97:1086-1091.
131. Bochner BS. Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol. 2004;113:3-9; quiz 10.
132. Nagase H, Okugawa S, Ota Y, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003;171:3977-3982.
133. Oliveira SH, Lukacs NW. The role of chemokines and chemokine receptors in eosinophil activation during inflammatory allergic reactions. Braz J Med Biol Res. 2003;36:1455-1463.
134. Munitz A, Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy. 2004;59:268-275.
135. Munitz A, Bachelet I, Fraenkel S, et al. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol. 2005;174:110-118.
136. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147-174.
137. Boucheix C, Benoit P, Frachet P, et al. Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J Biol Chem. 1991;266:117-122.
138. Grimaldi JC, Yu NX, Grunig G, et al. Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol. 1999;65:846-853.
139. McGarry MP, Stewart CC. Murine eosinophil granulocytes bind the murine macrophage-monocyte specific monoclonal antibody F4/80 [see comments]. J Leukoc Biol. 1991;50:471-478.
140. Aizawa H, Zimmermann N, Carrigan PE, et al. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics. 2003;82:521-530.
141. Weller PF, Rand TH, Goelz SE, et al. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA. 1991;88:7430-7433.
142. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218-1222.
143. Kim MR, Manoukian R, Yeh R, et al. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood. 2002;100:2330-2340.
144. Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol. 2004;173:5909-5913.
145. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106:2375-2381.
146. Schramm C, Huber S, Protschka M, et al. TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. Int Immunol. 2004;16:1241-1249.
147. Iwasaki K, Torisu M, Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer. 1986;58:1321-1327.
148. Ohashi Y, Ishibashi S, Suzuki T, et al. Significance of tumor associated tissue eosinophilia and other inflammatory cell infiltrate in early esophageal squamous cell carcinoma. Anticancer Res. 2000;20:3025-3030.
149. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study. BMC Cancer. 2001;1:7.
150. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, et al. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer. 2000;88:1544-1548.
151. Goldsmith MM, Belchis DA, Cresson DH, et al. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg. 1992;106:27-33.
152. Horiuchi K, Mishima K, Ohsawa M, et al. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J Surg Oncol. 1993;53:92-96.
153. Lowe D, Fletcher CD. Eosinophilia in squamous cell carcinoma of the oral cavity, external genitalia and anus - clinical correlations. Histopathology. 1984;8:627-632.
154. Pastrnak A, Jansa P. Local eosinophilia in stroma of tumors related to prognosis. Neoplasma. 1984;31:323-326.
155. Deron P, Goossens A, Halama AR. Tumour-associated tissue eosinophilia in head and neck squamous-cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 1996;58:167-170.
156. Sassler AM, McClatchey KD, Wolf GT, et al. Eosinophilic infiltration in advanced laryngeal squamous cell carcinoma. Veterans Administration Laryngeal Cooperative Study Group. Laryngoscope. 1995;105:413-416.
157. Thompson AC, Bradley PJ, Griffin NR. Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx. Am J Surg. 1994;168:469-471.
158. Leighton SE, Teo JG, Leung SF, et al. Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. Cancer. 1996;77:436-440.
159. Looi LM. Tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. A pathologic study of 422 primary and 138 metastatic tumors. Cancer. 1987;59:466-470.
160. Cuschieri A, Talbot IC, Weeden S. Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer. 2002;86:674-679.
161. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999;189:487-495.
162. Pretlow TP, Keith EF, Cryar AK, et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res. 1983;43:2997-3000.
163. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57:503-512.
164. Sacco M, Benedetti S, Cato EM, et al. Retrovirus-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice. Gene Ther. 1999;6:1893-1897.
165. Pericle F, Giovarelli M, Colombo MP, et al. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophilmediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol. 1994;153:5659-5673.
166. Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 2003;197:387-393.
167. Wong DT, Bowen SM, Elovic A, et al. Eosinophil ablation and tumor development. Oral Oncol. 1999;35:496-501.
168. Bassett EG. Infliltration of eosinophils into the modified connective tissue of oestrous and pregnant animals. Nature. 1962;194:1259-1261.
169. Bassett EG. Eosinophils and connective tissue catabolism. Biochem J. 1983;213:769-770.
170. Bassett EG, Baker JR, de Souza P. A light microscopical study of healing incised dermal wounds in rats, with special reference to eosinophil leucocytes and to the collagenous fibres of the periwound areas. Br J Exp Pathol. 1977;58:581-605.
171. Samoszuk MK, Espinoza FP. Deposition of autofluorescent eosinophil granules in pathologic bone marrow biopsies. Blood. 1987;70:597-599.
172. Samoszuk MK, Nguyen V, Gluzman I, et al. Occult deposition of eosinophil peroxidase in a subset of human breast carcinomas. Am J Pathol. 1996;148:701-706.
173. Samoszuk M, Lin F, Rim P, et al. New marker for blood vessels in human ovarian and endometrial cancers. Clin Cancer Res. 1996;2:1867-1871.
174. Huland E, Huland H. Tumor-associated eosinophilia in interleukin-2- treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol. 1992;118:463-467.
175. Simon HU, Plotz S, Simon D, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol. 2003;33:834-839.
176. Sosman JA, Bartemes K, Offord KP, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res. 1995;1:805-812.
177. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther. 2003;7:755-764.
178. Rivoltini L, Viggiano V, Spinazze S, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer. 1993;54:8-15.
179. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res. 2004;64:2175-2182.
180. Costello RT, Fauriat C, Sivori S, et al. NK cells: innate immunity against hematological malignancies? Trends Immunol. 2004;25:328-333.
181. Kataoka S, Konishi Y, Nishio Y, et al. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol. 2004;23:549-560.
182. Burgess SJ, Marusina AI, Pathmanathan I, et al. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol. 2006;176:1490-1497.
183. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 2003;4:1405-1409.
184. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-342.
185. Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165:2950-2954.
186. Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78:1-8.
187. Sun NK, Chao CC. The cytokine activity of HMGB1 - extracellular escape of the nuclear protein. Chang Gung Med J. 2005;28:673-682.
188. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004;173:307-313.
189. Dumitriu IE, Baruah P, Bianchi ME, et al. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol. 2005;35:2184-2190.
190. Matzinger P. An innate sense of danger. Ann N Y Acad Sci. 2002;961:341-342.
191. Goldman M, Le Moine A, Braun M, et al. A role for eosinophils in transplant rejection. Trends Immunol. 2001;22:247-251.
192. Braun MY, Desalle F, Le Moine A, et al. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma. Eur J Immunol. 2000;30:1290-1296.
193. Le Moine A, Surquin M, Demoor FX, et al. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. J Immunol. 1999;163:3778-3784.
194. Ackerman SJ, Liu L, Kwatia MA, et al. Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem. 2002;277:14859-14868.